Philips launches VitalMinds solution to address delirium in ICU

29 April 2019 (Last Updated April 29th, 2019 10:10)

Royal Philips has launched a multi-component solution, dubbed VitalMinds, as a non-pharmacological method for reducing delirium in intensive care unit patients.

Philips launches VitalMinds solution to address delirium in ICU
Philips VitalSky personalised light therapy system encourages natural sleep-wake rhythm for patients in the ICU. Credit: © Koninklijke Philips N.V.

Royal Philips has launched a multi-component solution, dubbed VitalMinds, as a non-pharmacological method for reducing delirium in intensive care unit (ICU) patients.

The solution involves a CE marked personalised light therapy system called VitalSky, which offers a circadian-effective programme to support the patients’ sleep-wake rhythm.

This programme uses a spectrum of glare-free white light to simulate the natural progression of daylight. The light is provided by a luminous LED ceiling and can be customised based on the requirements of the individual patient.

“With VitalMinds, we have developed a new concept that combines light and sound management, circadian-effective light therapy, staff training and consulting services.”

The system offers the additional option of playing calming nature scenes in full-colour and soft-focus video. In the future, the system may also enable cognitive training.

The different programmes and settings of the system can be regulated using a portable user interface.

Royal Philips Monitoring Analytics business leader Felix Baader said: “With VitalMinds, we have developed a new concept that combines light and sound management, circadian-effective light therapy, staff training and consulting services, to help hospitals reduce delirium and improve patient recovery in the ICU.

“This integrated approach is based on international ICU guidelines and supports hospitals in achieving the quadruple aim to improve patient and staff experience, deliver better health outcomes, and drive lower costs in intensive care medicine.” 

The system is currently available in Germany, Austria, Switzerland, Finland and Sweden. Additional roll-outs across other European countries will be carried out over the next two years.